VNX-202 / Vironexis Biotherapeutics - LARVOL DELTA

Gene Therapy for HER-Positive Cancer (SENTRY-HER2) (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Vironexis Biotherapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Gene Therapies • Oncology • Solid Tumor

Gene Therapy for HER-Positive Cancer (SENTRY-HER2) (clinicaltrials.gov) - P1/2 | N=27 | Not yet recruiting | Sponsor: Vironexis Biotherapeutics Inc.

First-in-human • New P1/2 trial • Gene Therapies • Oncology • Solid Tumor